Overview
To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation
Description
To explore the effect of letermovir prophylaxis on cytomegalovirus-specific and other lymphocyte subsets immune reconstitution post unrelated cord blood transplantation, and to analyze the potential mechanism and risk factors of late CMV reactivation after letermovir discontinuation.
Eligibility
Inclusion Criteria:
- Patients are receiving a first unrelated cord blood transplantation (UCBT).
- Patients start letemovir prophylaxis within 0-28 days post UCBT.
Exclusion Criteria:
- Patients having active CMV DNAemia at the time of letermovir initiation.
- Patients recruited in a clinical study on an anti-CMV trial.